Higher level of IL-6 in Jaccoud’s arthropathy secondary to systemic lupus erythematosus: a perspective for its treatment?

被引:0
|
作者
Ajax Mercês Atta
Rodrigo C. Oliveira
Isabela S. Oliveira
Mariana P. Menezes
Taciana P. S. Santos
Maria Luiza B. Sousa Atta
Mittermayer B. Santiago
机构
[1] Universidade Federal da Bahia,Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia
[2] Universidade Federal da Bahia,Programa de Pós
[3] Escola Bahiana de Medicina e Saúde Pública,Graduação em Imunologia
来源
关键词
Jaccoud’s arthropathy; Systemic lupus erythematosus; Cytokines; Interleukin-6;
D O I
暂无
中图分类号
学科分类号
摘要
Jaccoud’s arthropathy (JA) is a condition characterized clinically by ‘reversible’ joint deformities along with an absence of articular erosions on a plain radiograph. The main clinical entity associated with JA is systemic lupus erythematosus (SLE) with a prevalence of around 5 %. The aim of the present study was to compare the inflammatory markers including cytokine levels in blood of SLE patients with and without JA. Patients with diagnosis of SLE as defined by ACR criteria were screened and divided in two groups, one with JA and one control group without JA. Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), complement C3 and C4 levels antinuclear antibodies (ANA), anti-dsDNA antibodies and serum levels of IL-2, IL-6, IL-10, IL-21, IL-22 and TNF-α were determined in all patients. Eighty female patients with SLE, 18 (22.5 %) with JA and 62 (77.5 %) without JA, were included in this study. JA patients had higher disease duration (p = 0.008), ESR (p < 0.001), CRP level (p = 0.002), ANA titer (p < 0.001) and dsDNA antibody level (p = 0.009). The serum levels of IL-2, IL-10, IL-21, IL-22 and TNF-α were not significantly different between the two groups (p > 0.05), but the level of IL-6 was higher in JA group (p < 0.001). The serum level of IL-6 might have a correlation with JA secondary to SLE.
引用
收藏
页码:167 / 170
页数:3
相关论文
共 50 条
  • [31] NOVEL POLYMORPHISMS OF THE IL-6 GENE IN SYSTEMIC LUPUS-ERYTHEMATOSUS (SLE)
    LINKERISRAELI, M
    PREHN, J
    WALLACE, D
    LI, L
    TOYODA, H
    CHEN, T
    KLINENBERG, JR
    FASEB JOURNAL, 1992, 6 (04): : A1406 - A1406
  • [32] Changes of Serum IL-6, IL-17, and Complements in Systemic Lupus Erythematosus Patients
    Tang, Yamei
    Tao, Huai
    Gong, Yuji
    Chen, Fang
    Li, Cunyan
    Yang, Xiudeng
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2019, 39 (07): : 410 - 415
  • [33] Current treatment of systemic lupus erythematosus: a clinician's perspective
    Katarzyna, Pawlak-Bus
    Wiktor, Schmidt
    Ewa, Dudziec
    Piotr, Leszczynski
    RHEUMATOLOGY INTERNATIONAL, 2023, 43 (08) : 1395 - 1407
  • [34] Current treatment of systemic lupus erythematosus: a clinician's perspective
    Pawlak-Buś Katarzyna
    Schmidt Wiktor
    Dudziec Ewa
    Leszczyński Piotr
    Rheumatology International, 2023, 43 : 1395 - 1407
  • [35] Novel alleles of the IL-6 gene minisatellite are associated with systemic lupus erythematosus (SLE) and with differential IL-6 expression.
    Linker-Israeli, M
    Wallace, DJ
    Michael, D
    Prehn, J
    Nand, R
    Taylor, KD
    Paul-Labrador, M
    Honda, M
    Fischel-Ghodsian, N
    Fraser, PA
    Klinenberg, JR
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S282 - S282
  • [36] IL-6 and CH50 for monitoring of disease activity in systemic lupus erythematosus
    Han, Mi-Soon
    Park, Yongjung
    Kim, Hyon-Suk
    CYTOKINE, 2014, 70 (01) : 44 - 44
  • [37] IL-6 promoter polymorphism (−174G/C) and systemic lupus erythematosus
    Enas Hamdy
    Reham A. Aleem Afify
    Abeer Kamal
    Doaa Abass
    Manal Mahmoud
    Comparative Clinical Pathology, 2012, 21 (5) : 975 - 979
  • [38] Anti-citrullinated peptide and rheumatoid factor-IgM, -IgA, -IgG antibodies in systemic lupus erythematosus with Jaccoud's arthropathy
    Hrncir, Z
    Drahosova, M
    Bradna, P
    Soukup, T
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 241 - 241
  • [39] Interleukin 6 (IL-6) Deficiency Delays Lupus Nephritis in MRL-Faslpr Mice: The IL-6 Pathway as a New Therapeutic Target in Treatment of Autoimmune Kidney Disease in Systemic Lupus Erythematosus
    Cash, Hannes
    Relle, Manfred
    Menke, Julia
    Brochhausen, Christoph
    Jones, Simon A.
    Topley, Nicholas
    Galle, Peter R.
    Schwarting, Andreas
    JOURNAL OF RHEUMATOLOGY, 2010, 37 (01) : 60 - 70
  • [40] ELEVATED LEVELS OF ENDOGENOUS IL-6 IN SYSTEMIC LUPUS-ERYTHEMATOSUS - A PUTATIVE ROLE IN PATHOGENESIS
    LINKERISRAELI, M
    DEANS, RJ
    WALLACE, DJ
    PREHN, J
    OZERICHEN, T
    KLINENBERG, JR
    JOURNAL OF IMMUNOLOGY, 1991, 147 (01): : 117 - 123